Dow Jones

44,565.07

0.92%

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Home
Investing
ETFs
UK
LSE
Ls 2x Salesforc (CRME)
Ls 2x Salesforc (CRME) News

Ls 2x Salesforc (CRME)

Ls 2x Salesforc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:CRME

1 2 3 4 Next >>

Date	Time	Source	Headline	Symbol	Company
24/04/2023	14:47	UK Regulatory	Leverage Shares PLC Issuer Call Redemption Confirmation	LSE:CRME	Ls 2x Salesforc
21/12/2009	22:05	PR Newswire (US)	Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans	LSE:CRME
17/12/2009	23:00	PR Newswire (US)	Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study	LSE:CRME
09/11/2009	13:40	PR Newswire (US)	Cardiome Reports Third Quarter Results	LSE:CRME
06/11/2009	23:00	PR Newswire (US)	Cardiome to Release Third Quarter Results	LSE:CRME
02/11/2009	19:35	PR Newswire (US)	Cardiome To Present At Oppenheimer Healthcare Conference	LSE:CRME
28/10/2009	20:58	PR Newswire (US)	Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial	LSE:CRME
17/10/2009	00:54	PR Newswire (US)	Cardiome Pharma Corp. Announces Final Results of Tender Offer	LSE:CRME
14/10/2009	10:00	PR Newswire (US)	Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer	LSE:CRME
01/09/2009	18:57	PR Newswire (US)	Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer	LSE:CRME
28/08/2009	17:30	PR Newswire (US)	Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of	LSE:CRME
25/08/2009	21:11	PR Newswire (US)	Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares	LSE:CRME
11/08/2009	11:45	PR Newswire (US)	Cardiome Reports Second Quarter Results	LSE:CRME
10/08/2009	23:45	PR Newswire (US)	Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement	LSE:CRME
10/08/2009	20:35	PR Newswire (US)	Cardiome to Hold Conference Call	LSE:CRME
03/08/2009	21:16	PR Newswire (US)	Cardiome Announces Management Transition	LSE:CRME
28/07/2009	15:45	PR Newswire (US)	Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.	LSE:CRME
19/05/2009	12:30	PR Newswire (US)	Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective	LSE:CRME
15/05/2009	20:05	PR Newswire (US)	Cardiome Reports First Quarter Results	LSE:CRME
08/04/2009	22:13	PR Newswire (US)	Cardiome to Hold Conference Call	LSE:CRME
28/11/2008	22:31	PR Newswire (US)	Cardiome Discloses Chairman And CEO's Involuntary Share Sale	LSE:CRME
14/11/2008	23:40	PR Newswire (US)	Cardiome Reports Third Quarter Results	LSE:CRME
24/10/2008	02:40	PR Newswire (US)	Cardiome Announces Filing Of Shelf Registration Statement	LSE:CRME
09/10/2008	16:20	PR Newswire (US)	Cardiome Provides Regulatory Update	LSE:CRME
12/08/2008	20:05	PR Newswire (US)	Cardiome Reports Second Quarter Results	LSE:CRME
11/08/2008	20:30	PR Newswire (US)	Cardiome to Release Second Quarter Results and Hold Conference Call	LSE:CRME
11/08/2008	13:18	PR Newswire (US)	Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)	LSE:CRME
23/07/2008	18:10	PR Newswire (US)	Cardiome Announces Preferred Share Financing	LSE:CRME
14/07/2008	12:25	PR Newswire (US)	Cardiome Announces Positive Phase 2b Results For Oral Vernakalant	LSE:CRME
13/07/2008	16:00	PR Newswire (US)	Cardiome To Hold Conference Call	LSE:CRME